In recent years, treatment options for patients with advanced biliary tract cancer (BTC) have increased significantly due to the positive results from phase 2/3 clinical trials of immune checkpoint inhibitors, combined with chemotherapy, and molecularly targeted agents. These advances have led to the need for molecular testing to identify actionable alterations and patients amenable to targeted therapies. However, these improvements have brought with them many questions and challenges, including the identification of resistance mechanisms and therapeutic sequences. In this Series paper we aim to provide an overview of the current systemic treatment options for patients with BTC, highlighting disparities in access to innovative treatments and molecular testing across European countries, which lead to inequalities in the possibilities of treating patients with advanced BTC. We also discuss how ongoing European collaborative projects, such as the COST Action Precision-BTC-Network CA22125, supported by COST (European Cooperation in Science and Technology), linked to the European Network for the Study of Cholangiocarcinoma (ENSCCA), can help overcome these disparities and improve the current scenario.
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe / Rimassa, L.; Lamarca, A.; O'Kane, G. M.; Edeline, J.; Mcnamara, M. G.; Vogel, A.; Fassan, M.; Forner, A.; Kendall, T.; Adeva, J.; Casadei-Gardini, A.; Fornaro, L.; Hollebecque, A.; Lowery, M. A.; Macarulla, T.; Malka, D.; Mariamidze, E.; Niger, M.; Ustav, A.; Bridgewater, J.; Macias, R. I. R.; Braconi, C.. - In: THE LANCET REGIONAL HEALTH. EUROPE. - ISSN 2666-7762. - 50:(2025). [10.1016/j.lanepe.2024.101170]
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Casadei-Gardini A.;
2025-01-01
Abstract
In recent years, treatment options for patients with advanced biliary tract cancer (BTC) have increased significantly due to the positive results from phase 2/3 clinical trials of immune checkpoint inhibitors, combined with chemotherapy, and molecularly targeted agents. These advances have led to the need for molecular testing to identify actionable alterations and patients amenable to targeted therapies. However, these improvements have brought with them many questions and challenges, including the identification of resistance mechanisms and therapeutic sequences. In this Series paper we aim to provide an overview of the current systemic treatment options for patients with BTC, highlighting disparities in access to innovative treatments and molecular testing across European countries, which lead to inequalities in the possibilities of treating patients with advanced BTC. We also discuss how ongoing European collaborative projects, such as the COST Action Precision-BTC-Network CA22125, supported by COST (European Cooperation in Science and Technology), linked to the European Network for the Study of Cholangiocarcinoma (ENSCCA), can help overcome these disparities and improve the current scenario.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
